Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-38656
Abduljalil, K; Frank, D; Gaedigk, A; Klaassen, T; Tomalik-Scharte, D; Jetter, A; Jaehde, U; Kirchheiner, J; Fuhr, U (2010). Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan. Clinical Pharmacology and Therapeutics, 88(5):643-651.
|Creative Commons: Attribution 3.0|
The pharmacokinetics of dextromethorphan (DM) is markedly influenced by cytochrome P450 2D6 (CYP2D6) enzyme polymorphisms. The aim of this study was to quantify the effects of the CYP2D6*1, *2, and *41 variants on DM metabolism in vivo and to identify other sources of pharmacokinetic variability. Concentrations of DM and dextrorphan (DO) in plasma and urine were evaluated in 36 healthy Caucasian men. These volunteers participated in three clinical studies and received a single oral dose of 30 mg DM-HBr. Data were modeled simultaneously using the population pharmacokinetics NONMEM software. A five-compartment model adequately described the data. The activity levels of the alleles assessed differed significantly. The clearance attributable to an individual CYP2D6*1 copy was 2.5-fold higher as compared with CYP2D6*2 (5,010 vs. 2,020 l/h), whereas the metabolic activity of CYP2D6*41 was very low (85 l/h). Urinary pH was confirmed as a significant covariate for DM renal clearance. These results refine genotype-based predictions of pharmacokinetics for DM and presumably for other CYP2D6 substrates as well.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Clinical Pharmacology and Toxicology|
|DDC:||610 Medicine & health|
|Deposited On:||03 Jan 2011 13:10|
|Last Modified:||05 Dec 2013 08:20|
|Citations:||Web of Science®. Times Cited: 14|
Scopus®. Citation Count: 18
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page